DAY ONE BIOPHARMACEUTICALS I (DAWN)
US23954D1090 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 230.78M | 85.30M | 284.30M | 43.70M | 27.30M | |||
| Marketable Securities | 135.56M | 257.00M | N/A | N/A | N/A | |||
| Other Current Assets | 8.93M | 5.60M | 5.10M | 1.30M | 0.00 | |||
| Total Current Assets | 375.27M | 347.90M | 289.40M | 45.10M | 27.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 560.00K | 700.00K | 300.00K | 500.00K | N/A | |||
| Investments And Advances | 214.00K | 500.00K | 200.00K | 100.00K | N/A | |||
| Total Non-Current Assets | 774.00K | 1.20M | 400.00K | 600.00K | 0.00 | |||
| TOTAL ASSETS | 376.05M | 349.10M | 289.80M | 45.70M | 27.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 25.89M | 16.20M | 6.80M | 1.80M | 500.00K | |||
| Accounts Payable | 2.58M | 300.00K | 1.70M | 200.00K | 100.00K | |||
| Other Current Liabilities | 1.04M | 200.00K | 100.00K | 0.00 | 1.50M | |||
| Total Current Liabilities | 29.51M | 16.60M | 8.70M | 2.00M | 2.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 0.00 | 400.00K | 0.00 | 200.00K | 0.00 | |||
| Total Non-Current Liabilities | 0.00 | 400.00K | 0.00 | 5.90M | 5.50M | |||
| TOTAL LIABILITIES | 29.51M | 17.00M | 8.70M | 7.90M | 7.50M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -458.58M | -269.70M | -127.50M | -56.80M | -12.80M | |||
| Additional Paid In Capital | 805.11M | 601.80M | 408.60M | N/A | N/A | |||
| Minority Interest | 0.00 | 0.00 | -97.89M | 9.04M | 9.85M | |||
| Common Shares | 9.00K | 0.00 | 0.00 | 94.60M | 32.60M | |||
| Other Shareholders' Equity | 9.00K | -100.00K | N/A | N/A | N/A | |||
| Shares Outstanding | 87.23M | 73.50M | 62.00M | 60.30M | 60.30M | |||
| Tangible Book Value per Share | 3.97 | 4.52 | 4.53 | -0.90 | -0.18 | |||
| Total Shareholders' Equity | 346.54M | 332.00M | 281.10M | 37.80M | 19.80M | |||
| TOTAL LIABILITIES AND EQUITY | 376.05M | 349.10M | 289.80M | 45.70M | 27.30M | |||
| Statistics | ||||||||
| Current Ratio | 12.72 | 20.96 | 33.26 | 22.55 | 13.65 | |||
| Return On Assets (ROA) | -50.24% | -40.73% | -58.88% | -88.64% | -46.26% | |||
| Return On Equity (ROE) | -54.52% | -42.83% | -60.70% | -107.17% | -63.79% | |||
All data in USD